PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportslung diseases
MeSH D008171 - lung diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D012140:Respiratory tract diseases
53 Companies
6 Drugs
$
Success rate
D008171: 
Lung diseases
3 Companies
2 Drugs
$
Success rate
D001261:Pulmonary atelectasis
0 Companies
0 Drugs
Success rate
D003074:Solitary pulmonary nodule
0 Companies
0 Drugs
Success rate
D003550:Cystic fibrosis
35 Companies
15 Drugs
$
Success rate
D006469:Hemoptysis
0 Companies
0 Drugs
Success rate
D006976:Pulmonary hypertension
101 Companies
21 Drugs
$
Success rate
D008169:Lung abscess
0 Companies
0 Drugs
Success rate
D008172:Fungal lung diseases
0 Companies
0 Drugs
Success rate
D008173:Obstructive lung diseases
56 Companies
9 Drugs
$
Success rate
D008174:Parasitic lung diseases
0 Companies
0 Drugs
Success rate
D008175:Lung neoplasms
62 Companies
27 Drugs
$
Success rate
D011014:Pneumonia
70 Companies
20 Drugs
$
Success rate
D011649:Pulmonary alveolar proteinosis
0 Companies
0 Drugs
Success rate
D011654:Pulmonary edema
59 Companies
5 Drugs
$
Success rate
D011655:Pulmonary embolism
69 Companies
19 Drugs
$
Success rate
D011657:Pulmonary eosinophilia
1 Company
1 Drug
$
Success rate
D011668:Pulmonary veno-occlusive disease
0 Companies
0 Drugs
Success rate
D012128:Respiratory distress syndrome
51 Companies
5 Drugs
$
Success rate
D012587:Scimitar syndrome
0 Companies
0 Drugs
Success rate
D014397:Pulmonary tuberculosis
148 Companies
23 Drugs
$
Success rate
D015615:Congenital cystic adenomatoid malformation of lung
0 Companies
0 Drugs
Success rate
D016726:Pulmonary plasma cell granuloma
0 Companies
0 Drugs
Success rate
D017563:Interstitial lung diseases
0 Companies
0 Drugs
Success rate
D019568:Hyperlucent lung
0 Companies
0 Drugs
Success rate
D019896:Alpha 1-antitrypsin deficiency
0 Companies
0 Drugs
Success rate
D020065:Hepatopulmonary syndrome
0 Companies
0 Drugs
Success rate
D055370:Lung injury
0 Companies
0 Drugs
Success rate
D056586:Acute chest syndrome
0 Companies
0 Drugs
Success rate
D000097545:Pulmonary hemosiderosis
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
CSL Behring.alpha.1-proteinase inhibitor human Respreeza  2015-08-20   
RochePirfenidone Esbriet  2011-02-27 $749.525 M Y2022 
ViatrisPirfenidone Pirfenidone Viatris  2023-01-10   
Clinical Trials
Historical Success Rate
Phase 1
75%
21/28
Phase 2
54%
37/69
Phase 3
8%
7/85
Approved: 1Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
CSL Behring
.alpha.1-proteinase inhibitor human,
Bevifimod
Roche
Pirfenidone,
Mycophenolate sodium,
Benzocaine,
Transplatin,
Albumin,
Antithrombin iii,
Astegolimab,
Retinol,
Mk3475,
Q2w,
Gemcis,
Evidence
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use